SAVA Stock Summary and Trading Ideas (Cassava Sciences | NASDAQ:SAVA)

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Cassava Sciences trades on the NASDAQ stock market under the symbol SAVA.

As of December 26, 2025, SAVA stock price declined to $2.18 with 523,655 million shares trading.

SAVA has a beta of 1.50, meaning it tends to be more sensitive to market movements. SAVA has a correlation of 0.08 to the broad based SPY ETF.

SAVA has a market cap of $105.31 million. This is considered a Micro Cap stock.

In the last 3 years, SAVA traded as high as $42.20 and as low as $1.15.

The top ETF exchange traded funds that SAVA belongs to (by Net Assets): VTI, VXF, VHT, IWC, AVSC.

SAVA has underperformed the market in the last year with a price return of -15.8% while the SPY ETF gained +16.0%. SAVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -27.1% and -25.6%, respectively, while the SPY returned +4.6% and +1.5%, respectively.

SAVA support price is $2.11 and resistance is $2.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SAVA shares will trade within this expected range on the day.